Sensus Healthcare

156 articles about Sensus Healthcare

• Colorado State University, Flint Animal Cancer Center Applies Sensus Healthcare’s SRT Non-Surgical Treatment to Animal Care

  3/16/2021

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that the first canine patient was successfully treated with the company’s SRT-100™ system.

• Sensus Healthcare to Participate in Three Investment Conferences During the Month of March

  3/8/2021

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that Joe Sardano, Chairman and Chief Executive Officer, will participate in three virtual investment conferences during the month of March, as follows:

• Sensus Healthcare Reports Fourth Quarter and Full Year 2020 Financial Results

  2/25/2021

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and 12 months ended December 31, 2020.

• Sensus Healthcare Granted U.S. Patent for Three-Dimensional Beam Forming X-Ray SourcePatent covers beam splitting and sculpting capabilities of radiation to treat all types of solid tumors with Sculptura™ and potentially other devices

  2/23/2021

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that the U.S. Patent and Trademark Office has granted the Company Patent No. 10,607,802 B2, titled “Three-Dimensional Beam Forming X-Ray Source.”

• Sensus Healthcare to Host Fourth Quarter 2020 Financial Results and Business Update Conference Call on February 25, 2021

  2/18/2021

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 25, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter of 2020.

• Holy Name Medical Center in Teaneck, New Jersey Acquires Sensus Healthcare’s Low-dose Radiation Therapy System to Treat Pneumonia in COVID-19 Patients

  1/6/2021

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced Holy Name Medical Center in Teaneck, New Jersey has acquired a Sensus low-dose radiation therapy system for the treatment of pneumonia in COVID-19 patients.

• Sensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100™ SystemsAgreement is for the treatment of non-melanoma skin cancer and keloids, covers China and Hong Kong and is effective January 1, 2021

  12/15/2020

  Sensus Healthcare, Inc. announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong.

• Sensus Healthcare Announces CMS Sets Rates Higher for SRT Reimbursement

  12/8/2020

  Centers for Medicare & Medicaid Services sets a 66% increase in reimbursement for Radiation Treatment Delivery code 77401, and increases related Evaluation & Management codes

• Sensus Healthcare Announces Study Showing Single Low Dose of Superficial Radiation Therapy Prevents Keloid Recurrence Following Surgical Excision

  12/1/2020

  Sensus Healthcare, Inc. announces the publication of a prospective clinical study showing that a single low dose of superficial radiation therapy following excision of 14 keloids had an approximate 6.25% recurrence rate at six months, and for the 10 patients available for follow-up at 24 months none of the keloids had recurred.

• Sensus Healthcare Reports Third Quarter 2020 Financial ResultsConference call begins at 4:30 p.m. Eastern time today

  11/5/2020

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2020.

• Sensus Healthcare Appoints Megan Cornish to its Board of Directors

  11/5/2020

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Megan Cornish to its board of directors, effective January 1, 2021.

• Sensus Healthcare to Host Third Quarter 2020 Financial Results and Business Update Conference Call on November 5, 2020

  10/29/2020

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 5, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2020.

• Sensus Healthcare Announces Publication of Study Showing Use of Superficial Radiation Therapy Post-Keloidectomy Prevents Keloid Recurrence

  10/22/2020

  Keloid recurrence rate of 10.4% at 12 months for patients treated with SRT following keloidectomy compares with more than 80% with surgical excision alone

• Sensus Healthcare Reports Second Quarter 2020 Financial ResultsConference call begins at 4:30 p.m. Eastern time today

  8/6/2020

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and six months ended June 30, 2020.

• American Society of Radiologic Technologists Approves Sensus Healthcare’s SRT Systems for Continuing Education Units

  8/5/2020

  Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems

• Sensus Healthcare Acquires Two Mobile Aesthetic Laser Companies in Florida

  8/4/2020

  Establishes new line of business, adds recurring revenue stream while more than doubling dermatology customer base across the state

• Sensus Healthcare to Host Second Quarter 2020 Financial Results and Business Update Conference Call on August 6, 2020

  7/30/2020

  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 6, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcomi

• Sensus Healthcare Names Hoi-Bun “Benson” Suen Vice President of International Sales, Ships SRT-100™ to China

  7/28/2020

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Hoi-Bun “Benson” Suen as Vice President of International Sales.

• Evidence-Based Guidelines Issued by ASTRO Support Sensus Healthcare’s SRT Technology as the First-Line Alternative to Surgery for Treating Non-Melanoma Skin Cancer

  7/14/2020

  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, and the leading provider of superficial radiotherapy (SRT), reports that new guidelines issued by the American Society for Radiation Oncology (ASTRO) recommends SRT as the first-line alternative to surgery when treating patients with non-melanoma skin cancer (NMSC).

• Sensus Healthcare to Present at COVID-19 Webinar Hosted by Maxim Group on July 16th

  7/13/2020

  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, Sensus’ chief executive officer has been invited to present at the Re-Engaging Medical Practices in an Era of COVID-19  webinar, presented by Maxim Group and M-Vest on Thursday, July 16, 2020.